ID   A2L
AC   CVCL_X201
DR   Wikidata; Q54606625
RX   PubMed=6088881;
RX   PubMed=6310010;
RX   PubMed=6324641;
CC   Doubling time: 26 hours (Note=At 65th passage) (PubMed=6088881).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Pharynx, nasopharynx; UBERON=UBERON_0001728.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Transformed cell line
DT   Created: 17-07-14; Last updated: 29-06-23; Version: 8
//
RX   PubMed=6088881; DOI=10.1093/jnci/73.3.711;
RA   Takimoto T., Ogura H., Ohno S., Umeda R., Hatano M.;
RT   "Tumorigenicity of nasopharyngeal carcinoma hybrid cell line.";
RL   J. Natl. Cancer Inst. 73:711-715(1984).
//
RX   PubMed=6310010; DOI=10.1017/S0022215100094883;
RA   Takimoto T., Morishita K., Furukawa M., Umeda R., Hatano M.;
RT   "Establishment of Epstein-Barr virus (EBV) infection in epithelial
RT   cells derived from the nasopharynx by cell fusion.";
RL   J. Laryngol. Otol. 97:719-726(1983).
//
RX   PubMed=6324641; DOI=10.1177/000348948409300213;
RA   Takimoto T., Furukawa M., Hatano M., Umeda R.;
RT   "Epstein-Barr virus nuclear antigen-positive nasopharyngeal hybrid
RT   cells.";
RL   Ann. Otol. Rhinol. Laryngol. 93:166-169(1984).
//